The aim of this study is to compare the cost effectiveness of Sulfonylureas and DPP4-inhibitors in combination with Metformin among type2 diabetic patients diagnosed for 2-5 years. Glycemic status and other clinical outcome are compared in between two groups and ICER are compared.
New onset type2 diabetes mellitus diagnosed for 2 -5 years.
Taking either sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.
Age 18 years or above.
Both male and female.
Unwillingness to participate or unwillingness to give written informed consent.
Patients on Insulin therapy or monotherapy with metformin since the time of diagnosis.
Taking other than sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.
Diabetes related complications at the time of diagnosis.
patients attending out patient department of BIRDEM General hospital,Shahbag, Dhaka, which is a tertiary care hospital and patients attending Siddhirganj Diabetic center, a secondary care level diabetes center
Other
Retrospective
sulfonylurease with metformin, DPP4 inhibitors with Metformin
DrugOral hypoglycemic agents
HbA1c%
achievment of target HbA1 less than 7%
Insulin therapy
requirement of insulin therapy
hospitalization
requirement of hospitalization
3rd line therapy
addition of any 3rd drug
nephropathy
development of nephropathy
Click on the lead sponsor to view all of their trials.
